{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:36:55Z","timestamp":1792517815821,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Aim of the study<\/jats:title>\n                    <jats:p>Management of Chronic Prostatitis\/Primary Prostate Pain Syndrome (CP\/PPPS) is challenging and characterized by conflicting results. This study aimed to evaluate the efficacy of a food supplement based on Curcumin, Quercetin, Hyaluronic Acid and Chondroitin Sulfate (Ialuril Soft Gels\u00ae) in CP\/PPPS treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data of consecutive male patients who referred to our Institution for CP\/PPPS were prospectively collected between Oct-2022 and Jan-2023. Patients with maximum flow rate &amp;lt;15\u2005ml\/s, post-void residual &amp;gt;150\u2005ml and\/or previous prostate surgery were excluded. Variables including age, body mass index (BMI), prostate volume (PVol) and serum prostate specific antigen (PSA) were collected. Patients were asked to fulfil standardized questionnaires to assess severity of pain, lower urinary tract symptoms (LUTS) and erectile function, including Symptom Severity Index (SSI), Symptom Frequency Questionnaire (SFQ), National Institutes of Health Chronic Prostatitis Symptom Index (NHI\/CPSI) (pain and LUTS domains), International Prostate Symptom Score (IPSS) and Quality of Life score (IPSS-QoL), and International Index of Erectile Function (IIEF-5). Changes in standardized questionnaires were evaluated at baseline, 30- and 90-days after enrolment. Patients were administered 2 gelcaps of Ialuril Soft Gels\u00ae (curcumin 200\u2005mg, quercitin 200\u2005mg, hyaluronic acid 100\u2005mg, chondroitin sulfate 200\u2005mg) once a day for 60 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty patients were analysed. Baseline features were age [median 50 years (IQR 46\u201351)], BMI [24.2 (22.8\u201328.3)], PVol [42\u2005ml (30\u201352)], PSA [1.0\u2005ng\/ml (0.8\u20131.8)], SSI [54 (27\u201355)], SFQ [20 (13\u201326)], NHI\/CPSI [pain domain 10 (8\u201313); LUTS domain 7 (4\u20138)], IPSS [13 (10\u201318)], IPSS-QoL [3 (2\u20133)] and IIEF-5 [17 (14\u201322)]. SSI and SFQ scores showed statistically significant differences both at 30- [SSI 45 (22\u201349),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001; SFQ 16 (11\u201320),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035] and 90-days [SSI 33 (17\u201342),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001; SFQ 13 (9\u201316),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001]. IPSS and NHI\/CPSI pain and LUTS domains showed statistically significant differences at 30-days [IPSS 12 (10\u201313),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002; NHI\/CPSI pain domain 6 (5\u20139),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001; NHI\/CPSI LUTS domain 7 (2\u20139),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033, respectively], but not at 90-days (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). IPSS-QoL and IIEF-5 scores did not report any statistically significant difference during follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.23, respectively). No adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ialuril Soft Gels\u00ae seems to be effective in reducing the severity of pain and urinary symptoms in CP\/PPPS patients at short-term follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2025.1700681","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:30:00Z","timestamp":1762756200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term results of curcumin, quercetin, hyaluronic acid and chondroitin sulfate (Ialuril Soft Gels\u00ae) in the management of chronic prostatitis\/primary prostate pain syndrome: a single-center prospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Valerio","family":"Iacovelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vittori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Antonino Maria","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Brocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","volume-title":"EAU Guidelines on Chronic Pelvic Pain","author":"Engeler","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/nau.24846","article-title":"International continence society (ICS) report on the terminology for sexual health in men with lower urinary tract (LUT) and pelvic floor (PF) dysfunction","volume":"41","author":"Kocjancic","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"B4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/pcan.2016.8","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: a review of evaluation and therapy","volume":"19","author":"Polackwich","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ucl.2011.05.003","article-title":"Quercetin for chronic prostatitis\/chronic pelvic pain syndrome","volume":"38","author":"Shoskes","year":"2011","journal-title":"Urol Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pros.23536","article-title":"Quercetin protects against chronic prostatitis in rat model through NF-\u03baB and MAPK signaling pathways","volume":"78","author":"Meng","year":"2018","journal-title":"Prostate"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.23736\/S0393-2249.20.03672-3","article-title":"The role of glycosaminoglycans in the management of chronic pelvic pain: a systematic review","volume":"72","author":"Iacovelli","year":"2020","journal-title":"Minerva Urol Nefrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/01.ju.0000100088.70887.29","article-title":"Low agreement between previous physician diagnosed prostatitis and national institutes of health chronic prostatitis symptom index pain measures","volume":"171","author":"Roberts","year":"2004","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.ijantimicag.2007.08.028","article-title":"Epidemiology of prostatitis","author":"Krieger","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"B11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/bju.14988","article-title":"Pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome: a Cochrane systematic review","volume":"125","author":"Franco","year":"2020","journal-title":"BJU Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5534\/wjmh.190091","article-title":"Herbal phytotherapy in chronic nonbacterial prostatitis","author":"Park","year":"2009","journal-title":"World J Mens Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11934-023-01150-z","article-title":"Prostatitis: a review","volume":"24","author":"Yebes","year":"2023","journal-title":"Curr Urol Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4081\/aiua.2018.4.227","article-title":"Multidisciplinary approach to prostatitis","volume":"90","author":"Magri","year":"2019","journal-title":"Arch Ital Urol Androl"},{"key":"B15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0090-4295(00)00685-3","article-title":"Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial","volume":"56","author":"Nickel","year":"2000","journal-title":"Urology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/01.ju.0000159198.83103.01","article-title":"Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo-controlled study","volume":"173","author":"Nickel","year":"2005","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pathophysiology29030028","article-title":"Oral preparation of hyaluronic acid, chondroitin sulfate, curcumin, and quercetin (Ialuril\u00ae Soft Gels) for the prevention of LUTS after intravesical chemotherapy","volume":"29","author":"Manfredi","year":"2022","journal-title":"Pathophysiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","article-title":"The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)","volume":"112","author":"Gandaglia","year":"2013","journal-title":"BJU Int"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1700681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:30:00Z","timestamp":1762756200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1700681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":18,"alternative-id":["10.3389\/fsurg.2025.1700681"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2025.1700681","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1700681"}}